

QUARTERLY AND YEARLY COMPANY INFORMATION AND UPDATED
DISCLOSURE STATEMENT MARCH 31, 2012

Part A General Company Information

Item 1.

NAME:

CARDIO INFRARED TECHNOLOGIES, INC.

(Cardio Infrared Technologies, Inc Merged with Omega Mining & Exploration Corp. In July 2007 and changed the name in August 2007)

Stock Symbol (CDOI) was changed in May 2009 by a stock reverse

Stock Symbol (CIRT)

(The stock symbol was formerly owned by CIrtran Corp., which is not affiliated in any way.)

FORMERLY LISTED AS

Omega Mining & Exploration Corp Until Aug 2007

WIDE Entertainment, Inc Until Sept 2005

FACE Biometrics, Inc. Until March 2005

RTS Golf, Inc Until November 2004

Item II.

ADDRESS

Cardio Infrared Technologies, Inc
99 Fountainhead Cir.
Henderson, NV 89052
801-558-9646

Website;
www.cardioinfraredtech.com

Emails
waynebailey@cardioinfraredtech.com
wbailey@thebiofit.com
wbvalley@aol.com

Address to
Wayne Bailey CEO
801-558-9646

Item III.

Jurisdiction and date of the incorporation.

Change of Jurisdiction Wyoming, August 6, 2010

Merger and change of Jurisdiction Nevada, November 20, 2007

Original Incorporation Washington, September 28, 1995

Amended for Name
Washington, July 16, 2007
From:
Omega Mining & Exploration Corp.
To
Cardio Infrared Technologies, Inc

Amended for Name
Washington, August 31, 2005
From:
WIDE Entertainment, Inc
To:
Omega Mining & Exploration Corp.

Amended for Name
Washington, February 22, 2005
From:
FACE Biometrics, Inc.
To:
WIDE Entertainment, Inc

Amended for Name
Washington, November 8, 2004
From:
RTS Golf, Inc
To:
FACE Biometrics, Inc

Part B Share Structure

Item IV The title and class of securities outstanding

The company has 3,000,000,000 common shares authorized at .000001 Par, 371,367,144 issued and outstanding as of March 31, 2012 of which 170,700,160 is free trading.

The company has Six Classes of Preferred Stock all at .001 par value

1. Preferred A -1 Stock 1,000,000 shares authorized 20,000 issued and outstanding
2. Preferred B-1 Stock 1,000,000 Shares authorized 254,440 issued and outstanding
3. Preferred C-1 Stock 1,000,000 Shares authorized 10,000 issued and outstanding
4. Preferred A-2 Stock 1,000,000 Shares authorized 20,000 issued and outstanding
5. Preferred B-2 Stock 1,000,000 Shares authorized 479,324 issued and outstanding
6. Preferred C-2 Stock 1,000,000 Shares Authorized -0- issued and outstanding

Total number of beneficial Shareholders is 152

Total number of shareholders of record is 117

Part C Business Information

Item VII

Name and Address of Transfer Agent:

Action Stock Transfer Corp
7069 S. Highland Dr., Suit 300
Salt Lake City, Utah 84121
801-274-1088
Fax 801-274-1099
Registered with the SEC

Item: VIII

Nature of the business:

A.

Cardio Infrared Technologies Inc.
Is a C Corporation

The business started in February 2006

The Fiscal Year is December 31

There has never been a filing in bankruptcy, receivership

The issuer is not now nor has ever been a shell company.

Merged with Cardio Infrared Technologies, Inc in July 2007

All notes payable are being paid according to the terms or according to agreement.

Control of the company changed in July 2007

The company started doing a 504 offering in December 2007

No 504 offering after January 2009

There is no pending or threatened legal action

B.

Business Description:

- Cardio Infrared Technologies, Inc. is a leading-edge developer and manufacture of fitness and weight loss equipment and products.
- First Phase of the Clinical Trials have been completed at a FDA-certified facility in Philadelphia directed by Dr. Richard M. Goldfarb M.D., FACS and the second and third phase is now completed and will be released as soon as possible.
- The Weight Loss, Fitness, Wellness, Nutrition and Anti-Aging Industry is an explosive growth market
 - The prevalence of over weight and obesity in the United States continues to increase at alarming levels. One third of the adult population is currently overweight or obese, and preadolescent and adolescent overweight/obesity is also on the rise.
 - According to leading experts, overweight/obesity is the second leading cause of preventable death particularly in this country but on the rise around the world.
 - Most adults don't get enough physical activity. Exercise can improve health impairments and prevent some diseases. It can also improve mood and emotional well being. However the key to a sensible workout is to take it slowly and to do it regularly.
 - Cardiovascular training, resistance training or weightlifting, flexibility training and good nutrition can also dramatically slow down the aging process.

Unique Selling Points

- Couples a cardio workout with the use of infrared heat.
- Detoxifies the body naturally.
- Uses infrared heat to stimulate the body's immune system.
- Helps Reduces inflammation from rheumatoid arthritis.
- Reduces physiological and mental/emotional stress.
- The infrared will counteract Seasonal Affective Disorder (SAD).
- Accelerates calorie burn and controls weight.
- Weight Loss and Fitness
 - The Bike is programmed to step a client through a 40-minute cardio workout that is based on keeping the heart rate in the fat burning range. The bike adjusts the resistance for the user who simply needs to keep a steady speed and the bike does everything else.
 - The unique feature of the Bike is that it uses infrared lamps to increase the calories burned by a factor of up to 10 times the normal amount burned in a 40-minute workout. This is accomplished by increasing the body's core temperature and metabolism.

The company's Primary SIC code is 5091 Sporting and Recreation goods

The company's Secondary SIC code is 5049 Professional equipment misc.

The company is an operational company with existing sales and is also a development stage company developing new products based on the infrared and exercise concept.

The company is not now nor do we believe that it will fall under governmental regulations.

The amount of money spent over the last year on research and development is estimated at \$300,000 all of which the company has paid.

There has been no cost of compliance with environmental laws.

The company has a total of 4 employees.

Item IX

The nature of products.

The principal product of the Company is a new generation Infrared stationary bike. Which will be marketed into the health and wellness industry. Wellness Centers, Weight Loss Centers, Med Spas, Gyms, Doctors Offices, Day Spas, and other areas that are providing their clients with the latest and best type of service.

Distribution has been by direct sales and shows for the industries. The company is now setting up distributors around the world. We now have distributors in England, France, Germany, Poland, Spain Italy, Portugal, and Turkey.

The company has a unique type of equipment that gives it an advantage in that it combines the benefits of Infrared with light exercise to increase the metabolism, detoxification, overall well being, helping with arthritis, enhancing circulation in both deep and surface tissues, accelerating metabolism, boosting the immune system, and reducing pain and inflammation and numerous other benefits.

The company is not dependent on one or a few customers.

The company does not need any governmental approval however the equipment is in clinical trails in a FDA approved facility and we have made a filing with the FDA. The clinical trails are for marketing not governmental approval.

Item X

Cardio Infrared Technologies, Inc. Facilities.

Cardio Infrared Technologies, Inc has three facilities the first is

1848 West 11th Street Suite M, Upland, CA 91786

This facility is rented and is the company's warehouse for equipment. This facility has operated since March 2006.

99 Fountainhead Cir, Henderson, NV 89052

This facility is rented and is listed as the Corporate Headquarters.

Bucks County Clinical Research.

201 Sequoia Dr.

New Town, PA 18942

This facility is rented and operated by Bucks County Clinical Research the equipment is owed by the company.

DEA Project

24030 Mozzo

Bergamo C.F./P .iva 03572890162 Italy

This is our prototype and research facility. We are also doing some production work from this facility while we are setting up manufacturing in Las Vegas, NV

Part D Management and Control Structure

Item XI

The name of the chief executive officer, members of the board of directors, as well as control persons

A. Officers and Directors

Full Name. Wayne Keith Bailey

Directors.

1. Full Name Wayne K. Bailey
2. Business Address: 99 Fountainhead Cir.
Henderson, NV 89052
3. Employment History: Cardio Infrared Technologies Inc
April 1, 2007 to Present
Better Bodies Inc
September 2005 to Present
4. Compensation \$80,000 per year
5. Number of issuer's shares owned
Common Shares 200,666,924
Preferred Shares 40,000

B. Legal/Disciplinary None

C. Disclosure of Family Relationships None

D. Disclosure of Related Party Transactions.

1. Name of related Person Wayne Bailey
2. Related Person's interest Loans to Company
- 3 & 4 Approximate Dollar Value \$50,000 Plus interest
5. Mr. Bailey has loaned money to the company on an on going basis.

E. Disclosure of Conflicts of Interest. There are no conflicts of interest

Item XII Financial information for the companies most recent fiscal period

CARDIO INFRARED TECHNOLOGIES, INC
BALANCE SHEET
AS OF MARCH 31, 2012 AND MARCH 31, 2011

	<u>ASSETS</u>	UNAUDITED	UNAUDITED
Current Assets:			
Cash And Cash Equivalents	\$	41,559	\$
Receivables			7,000
Inventory		6,512	35,050
Clinical Trails		792,837	785,837
Total Current Assets		<u>840,908</u>	<u>827,887</u>
Other Assets		<u>3,723,685</u>	<u>3,707,653</u>
Total Assets	\$	<u><u>4,564,593</u></u>	\$ <u><u>4,535,540</u></u>
<u>LIABILITIES AND SHAREHOLDER'S EQUITY</u>			
Current Liabilities:			
Accounts Payable	\$		\$ 6,496
Notes payables - Current		<u>314,552</u>	<u>179,562</u>
Total Current Liabilities		314,552	186,058
Long-term Liabilities:		<u>61,330</u>	<u>58,830</u>
Total liabilities		<u>375,882</u>	<u>244,888</u>
Commitments		-	
Stockholders' Equity:			
Common stock: 3,000,000 shares authorized, \$0.000001 par value			
372,150,908 shares issued and outstanding		1,158	3,985
Additional paid-in-capital		4,866,565	4,953,364
Accumulated deficits		<u>(679,012)</u>	<u>(666,696)</u>
Total Stockholders' Equity		<u>4,188,711</u>	<u>4,290,653</u>
Total Liabilities And Stockholders' Equity	\$	<u><u>4,564,593</u></u>	\$ <u><u>4,535,541</u></u>

See accompanying notes to financial statements

CARDIO INFRARED TECHNOLOGIES, INC
STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDING MARCH 31, 2012 AND MARCH 31, 2011

	UNAUDITED	UNAUDITED
	<u> </u>	<u> </u>
Net revenue	\$ -	\$ 49,200
Cost of revenue	<u> </u>	<u>11,674</u>
Gross profit	<u>-</u>	<u>37,526</u>
Operating expenses		
Amortization and depreciation expenses		
General & administrative expenses	<u>(43,701)</u>	<u>57,272</u>
Total operating expenses	<u>(43,701)</u>	<u>57,272</u>
Income (Loss) from operations	<u>(43,701)</u>	<u>(19,746)</u>
Other income (expense):		
Other income		
Other Expense		
Interest expense	<u>5,000</u>	<u>11,000</u>
Total other income (expense)	<u>(5,000)</u>	<u>(11,000)</u>
Net profit (loss)	\$ <u><u>(48,701)</u></u>	\$ <u><u>(30,746)</u></u>

See accompanying notes to financial statements

CARDIO INFRARED TECHNOLOGIES, INC
STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS TO DATE ENDED MARCH 31, 2012 AND MARCH 31, 2011
UNAUDITED

	<u>2012</u>	<u>2011</u>
Cash Flows From Operating Activities		
Net Income (loss)	\$ (48,701)	\$ (30,746)
		-
Depreciation and amortization		-
(Increase) / decrease in assets:		
Accounts Receivable		(7,000)
Inventory/Clinical Trials		(790)
Other Assets	(5,534)	(35,000)
Prepaid Expenses	-	
Increase / (decrease) in liabilities:		
Commissions Payable	-	
Accrued Expenses	-	
Notes Payable	54,475	(31,344)
Accrued Interest	-	
Accounts Payable		
Net cash used in operating activities	<u>48,941</u>	<u>(104,880)</u>
Net cash Increase for period		
Cash Flows From Financing Activities		
Net cash provided by Financing Activities		106,723
Net Proceeds from the issuance of Preferred stock		
Net Proceeds from acquisition of assets		
Net Cash Provided by Financing Activities	<u>0</u>	<u>106,723</u>
Net Increase (Decrease) During the Period	48,941	1,843
Cash and cash equivalents, Beginning of the period	<u>(7,383)</u>	<u>(8,352)</u>
Cash and cash equivalent, End of the period	<u>\$ 41,558</u>	<u>\$ (6,509)</u>

See accompanying notes to financial statements

**Statement of Stockholders' Equity
For The Period Ended March 31, 2012**

	UNAUDITED				UNAUDITED
	Common Stock		Additional Paid-in	Retained Earnings	Stockholders' Equity
	Shares	Amount	Capital	(Deficit)	(Deficit)
Balance as of March 31, 2011	<u>30,201,000,442</u>	<u>30,201</u>	<u>4,407,596</u>	<u>(666,696)</u>	<u>3,771,102</u>
Cancel Stock Management	(27,000,000,000)	(27,000)	27,000		
Reverse Stock Split May 4, 2011 3000-1	1,067,122	1	4,437,796	(666,696)	3,771,101
DTC Rounding	22				
Stock Issued for Management	200,000,000	200	(200)		
Stock issued for Debt May, June 2011	100,300,000	103	9,927		10,030
Income or (Loss) as of June 30, 2011				39,187	39,187
Balance as of June 30, 2011	<u>301,367,144</u>	<u>304</u>	<u>4,447,523</u>	<u>(627,509)</u>	<u>3,820,318</u>
Stock Issued for Debt July 2011	65,000,000	65	6,435		6,500
Stock issued for Debt July 2011	5,000,000	5	4,995		5,000
Income or (loss) as of Sept 30, 2011				(7,398)	(7,398)
Balance at September 30, 2011	<u>371,367,144</u>	<u>374</u>	<u>4,458,953</u>	<u>(634,907)</u>	<u>3,824,420</u>
Income or (loss) as of Dec 31, 2011				4,596	4,596
Balance as December 31, 2011	<u>371,367,144</u>	<u>374</u>	<u>4,458,953</u>	<u>(630,311)</u>	<u>3,829,016</u>
Income or (loss) as of March 31, 2012				(48,701)	(48,701)

Balance as of March 31, 2012	<u>371,367,144</u>	<u>374</u>	<u>4,458,953</u>	<u>(679,012)</u>	<u>3,780,315</u>
---------------------------------	--------------------	------------	------------------	------------------	------------------

	Preferred Stock		Additional Paid-In	Retained Earnings	Stockholders' Equity
	Shares	Amount	Capital	(Deficit)	(Deficit)
Preferred A-1					
Balance Preferred A-1 March 31, 2012	<u>20,000</u>	<u>20</u>	<u></u>	<u></u>	<u>20</u>
Preferred B-1	-				
Balance December 31, 2009	308,750	309	87,496		87,805
Stock issued for Cash 1/31/10	3,000	3	29,997		30,000
Stock issued for Cash 2010	30,900	31	30,869		30,900
Cancel Shares Stock issued for Cash 4/29/11	(100,000)	(100)			(100)
	11,790	12	6,738		6,750
Balance Preferred B-1 March 31, 2012	<u>254,440</u>	<u>255</u>	<u>155,100</u>	<u></u>	<u>155,355</u>
Preferred C-1	-	-	-		-
Balance December 31, 2009	201,950	202	(2)		200
Stock Canceled	(191,950)	(192)	2		(190)
Balance Preferred C-1 March 31, 2012	<u>10,000</u>	<u>10</u>	<u>-</u>	<u></u>	<u>10</u>
Preferred A-2					
Balance December 31, 2009	-	-			
Stock issued for Services	20,000	20			20
Balance March 31, 2012	<u>20,000</u>	<u>20</u>	<u></u>	<u></u>	<u>20</u>
Preferred B-2	-	-	-		-
Balance December 31, 2009	48,155	48	120,337		120,385
stock issued for services	340,000	340			340
stock issued for Cash 2010	7,507	8	18,759		18,767

Stock issued for Cash 2010	83,662	84	113,416		113,500
Balance March 31, 2012	479,324	479	252,512		252,992
Preferred C-2 Balance March 31, 2012	-	-	-		-
Total Balance Preferred March 31, 2012	783,764	784	407,612		408,397
Total Balance of stock and equity	372,150,908	1,158	4,866,565	(679,012)	4,188,711

See accompanying notes to financial statements

Item XIV. Beneficial Owners.

<u>Principal Stockholder's Name</u>	<u>Number of Shares Owned</u>	<u>Percentage</u>
Wayne Bailey	200,666,924	54%

Item XV The name address, telephone number, and email address of each of the following outside providers.

1. Investment Banker None
2. Promoters None
3. Counsel Vincent and Rees, 175 South Main Suite 1530, Salt Lake City, Ut 84111
Phone 801-303-5730 drees@vincentrees.com
4. Accountant or Auditor None
5. Public Relations Consultant None
6. Investor Relations Consultant None

Item XVI. Managements Discussion and Analysis or Plan of Operation.

Cardio Infrared Technologies, Inc is a manufacturer, distributor and developer of innovative health care products. The main focus for the company is exercise equipment that combines infrared heat with exercise. The company controls the patents for this technology. This combination of infrared heat and exercise can increase the number of calories burned in a session by a factor of ten. Clinical trials have proven the calorie burn leading to weight loss and inch loss.

In January 2009 the Company became aware that the Unit it was then selling was a knockoff of a patented product. Patented in The United States and Europe with pending patent in other countries. The patent for the United States was issued on February 15, 2000 Patent number 6,024,760. On confirmation that there was a valid Patent and the unit known, as the CardioCor™ was in fact a knockoff the Company immediately cancelled all orders for that equipment. The supplier acknowledged that their product was a copy of an existing product and they also knew about the patent and decided to disregard the Patent. The management of the company decided that the patent was valid and enforceable and the company will not be involved with a counterfeit product or products. Management negotiated with the patent holder and reached a tentative agreement in April 2009. The agreement was signed in November 2009. The agreement is an exclusive license for all infrared patents that are held by Mr. Fabio Marchesi worldwide. The agreement called for the payment to Mr. Marchesi of \$50,000 in cash, 5,000 shares of Preferred B Stock restricted and a 7% royalty on all sales of infrared products or products that are based on the patents. After the license was signed the company started working on the design for the new units called BioFit™. The design was undertaken at D.E.A. Project in Bergamo, Italy. This is the company that designed and manufactured the original infrared bike called the Infracit. The new design was completed in February and the Company commissioned a Prototype to be built. The hardware on the prototype was complete in May 2010 but the software is still being completed. The BioFit™ infrared Bike is the ultimate design for the use of infrared and exercise, which is what the patent is all about. The new BioFit™ Infrared Bike will be produced and sold in the United States first, then exported to all parts of Europe. The Company displayed at the Anti-Aging Show in Las Vegas this past December 2011. The attendees comments were very positive and the reactions were “it is spectacular”.

The last two years has been a trying time for the company but a great ones. Acquiring the exclusive license for the patents will provide the company the opportunity to not only manufacture and market the unit and the technology but to develop a great number of additional equipment based on the

technology. The company has another piece of equipment that is in current development that utilizes the technology. The BioFit™ and the new BioDream™ will be featured at the Anti-Aging Show in Las Vegas this December. We have secured a larger booth for the show, which will allow room for both pieces of equipment and for demonstration space. This will be a great venue for the introduction both the BioFit™ and the BioDream™ both pieces of equipment feature all the best of the original technology and all of the latest developments and patented technology from Mr. Marchesi. The technology behind the patent and all of the knowledge that the inventor has accumulated is now at the disposal of the company. Mr. Marchesi will be featured at the show in December and will be there to answer questions and conduct seminars for the attending participants. Mr. Marchesi has joined the management team of Cardio as a consultant and will be an active member of the team. Mr. Marchesi has secured the distribution rights for all of our products in Italy.

The company believes that the new BioFit™ products will increase sales dramatically in the current market and open new markets for the company and its products. However to complete the new product, manufacture and distribute the company must seek additional capital. It will require \$500,000 to purchase the inventory and put the units into production this year. So far we have been unable to raise the required money due to Finra regulations that have stopped the ability to raise the funds through a PPM. Units are being produced in Italy and are being shipped to the Italian market. The projections for the new product far exceed the sales that have been experienced to date. The market demographics are much larger and the profit per unit is much higher than the existing products. The Company has a PPM that was being used to secure the money required to bring the production to the United States and the overall agreement was based on the stock price and conversion to free trading stock after a year but problems with the DTCC put a hold on the money for the time being. The company has expended considerable time and money trying to resolve the issue however the DTCC will not respond and apparently they do not have to abide by due process, they are just an independent bureaucracy. This action is injuring the stockholder, customers and the company. If they had not taken this action Cardio Infrared Technology Inc would be employing around 40 people in the United States by this time. Instead we are still getting our equipment manufactured in Italy at a much higher cost.

MARKET: The overall health and fitness industry is conservatively estimated at \$61 billion per year. The BioFit™ market is the health and fitness industry. There are fewer than 100 manufacturers of fitness equipment that operate in the US to meet this growing demand with combined annual sales of approximately \$3 billion. Larger companies include ICON Health & Fitness, Nautilus, Life Fitness, Precor, and Cybex. The growth forecasts for this market are estimated at 20% per annum. The BioFit™ and the BioDream™ will be able to capture 2.7% of this overall market. Which is \$81 million per year or 2,025 units per year. With a projected profit of \$12 to 16 Million.

The Company over the last year has secured \$300,000 in new funding. The company has used the money to secure the patents and to produce the Prototype. The money has allowed the company to come through a very tough time with no products to sell and now have our own line of products to manufacture and sell worldwide. The last two years has been a rebirth for the company and opportunities that are now available.

The company has elected to write off all of the inventory and other assets associated with the CardioCor™ unit and all costs that have been capitalized regarding market development, sales,

advertising costs and all other costs associated with the unit. The total write off including accounts receivable, deposits and inventory is \$635,581. This is a onetime charge. The inventory will be destroyed. The company will also contact all those who have purchased the CardioCor™ or the CelluBike™ and provide an upgrade to the new BioFit™. The old units will need to be destroyed.

New funding needs to be secured over the next few months and to that end the company has a Private Placement Memorandum that could be used to secure the new funding required for the production and marketing of the new units. With the funding production and marketing management feels that sales could very quickly reach \$500,000 per month with a profit of 20% of sales.

Market Trends

Four market trends combine to indicate a strong demand for health and fitness equipment and BioFit™ technology

1. Aging population;
2. Overall health consciousness of the population;
3. Rising health costs;
4. Innovation in fitness equipment.

Scientific studies have shown that a thirty- minute session using infrared wide-spectrum light can result in the loss of toxins and stored fats in the body by up to ten times the level traditional exercise alone can achieve. Infrared heat helps to promote the body's capillary system, which will increase blood circulation to the surface of the skin. Because of the deep penetrating heat from infrared, (infrared is the only heat that penetrates the skin's surface up to 3") health professionals have used infrared lamps for many years to treat muscle and joint problems. Infrared heat ensures an increased flow of oxygen rich blood to painful areas which helps to ease aches and pains, stiffness or soreness from arthritic conditions, tired overworked muscles or even poor posture.

Infrared combats the effects of daily stress and wakes up the immune system. Deep radiant infrared heat results in rising of the body's core temperature, which actually induces an artificial fever. This, in turn, activates and stimulates the body's immune system. Combined with the elimination of toxins and wastes from the body, the overall health and resistance to disease is noticeably improved so you feel and look better.

Health costs are rising faster every year, which has started a ground swell of people looking for ways to stay healthy longer.

INDUSTRY ANALYSIS

Market research in this area has outlined that the competition for this industry's highly profitable resources depends on a company's ability for unique product designs and effective marketing. Although established companies have some advantages in brand-name recognition, emerging companies can compete effectively to gain large market share through unique innovative product designs and effective/proven marketing skills

The market and the opportunity for this type of equipment are enormous and can be capitalized on quickly. However for a small company it will put a great strain on capital and on management. The rewards and profits will be well worth the risks and the work.

Item XVII List of securities offerings and shares issued for services in the past two years.

CARDIO INFRARED TECHNOLOGIES, INC

SHARES ISSUED

For Twenty Four Months Ended March 31, 2012

Common Stock	Shares
Stock Issued for Trust Oct 2009	900,000,000
Stock Issued on Trust Nov 2009	80,000,000
Stock Issued on Debt Conversion Nov & Dec	62,500,000
Stock Issued for Debt Conversion Feb 2010	100,000,000
Stock Issued for Services May 2010	1,500,000,000
Stock Issued on Debt Conversion May 2010	500,000,000
Stock Issued for Services Aug 2010	29,000,000,000
Stock Issued for Debt Conversion Aug 2010	12,200,000,000
Stock Issued for Debt-Conversion Dec 2010	600,000,000
Stock Issued for Debt Conversion March 2011	400,000,000
Canceled Stock March 2011	-12,000,000,000
Canceled Stock April 2011	-27,000,000,000
Stock Issued for Management	200,000,000
Stock Issued for Debt May June 2011	100,300,000
Stock Issued for Debt July 2011	70,000,000

Preferred Stock

B Stock Issued for Trust Nov 2009	300,000
B Stock Issued for Cash Nov 2009	5,000
B Stock Issued for Cash Dec 2009	3,750
C Stock Issued for Services Nov 2009	10,000
B-2 Stock Issued for Cash Nov 2009	40,755
B-2 Stock Issued for Cash Dec 2009	7,400
A-2 Stock Issued for Services May 2010	20,000
B-1 Stock Issued for Cash Jan 2010	7,400
B-1 Stock Issued for Cash May 2010	1,780
B-2 Stock Issued for Services	340,000
B-2 Stock Issued for Cash May 2010	40,972
B-2 Stock Issued for Cash July 2010	83,662
B-1 Stock Issued for Cash July 2010	33,900
B-1 Stock Issued for Cash April 2011	11,790

Item XVIII Material Contracts.

Cardio Infrared Technologies Inc entered into an Exclusive Intellectual License Agreement with Fabio Paolo Marchesi on November 21, 2009. The agreement gives Cardio Infrared Technologies Inc the exclusive rights to patents owned by Mr. Marchesi that has to do with the Combination of Infrared and Exercise. The agreement covers all of the rights to the patents in the US and worldwide to design develop and start the production and distribution of a new revolutionary, reliable, and modern Italian design, Infrared-bike and other cardio infrared systems or other systems, based on the best and correct application of his Intellectual Property and Patents, in the US market and worldwide. This agreement covers but is not limited to patents 6,024,760 and 6,409,744 and all other patents relating to infrared or the use of infrared. This agreement covers all intellectual property relating to infrared technology. The agreement is an exclusive license for all infrared patents that are held by Mr. Fabio Marchesi worldwide. The agreement called for the payment to Mr. Marchesi of \$50,000 in cash, 5,000 shares of Preferred B Stock restricted and a 7% royalty on all sales of infrared products or products that are based on the patents. After the license was signed the company started working on the design for the new units. The design was undertaken at D.E.A. Project in Bergamo, Italy. This is the company that designed and manufactured the original infrared bike called the Infracit

Item XIX Articles of Incorporation and Bylaws Posted

Item XX Purchase of Equity Securities by the Issuer and Affiliated Purchasers.

There has been no purchase of Equity Securities by the Issuer or Affiliates

Item IX: Issuer's Certifications

I, Wayne Keith Bailey, certify that:

1. I have reviewed this annual disclosure statement of Cardio Infrared Technologies, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial informant included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer and of, and for, the periods presented in this disclosure statement.

Date: May 14, 2012

____/s/Wayne Keith Bailey____ Wayne Keith Bailey, CEO

CARDIO INFRARED TECHNOLOGIES, INC. NOTES TO THE FINANCIAL STATEMENTS MARCH 31, 2012

Cardio Infrared Technologies Inc, [the "Company"] was engaged in the Sales and Distribution of the Cardio-Cor Infrared Bike. The Company was informed by the inventor of the Technology that the Cardio-Cor was a knockoff of a patent that was held by Fabio Marchesi patent Number 6,024,760. The Company discontinued the sales and distribution of the Cardio-Cor immediately. The Company acquired all of the rights to the patents for the United States and the world.

Effective November 21, 2009 as approved by our shareholders and board of directors, we entered into an agreement to acquire all of the rights and exclusive intellectual property license on all US and International patents held by Fabio Marchesi that concern the use of Infrared and Exercise or any use of infrared.

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since the second quarter of 2009. The ability to continue as a going concern is dependent upon the Companies ability to obtain the necessary capital to fund and put into production the New Infrared Equipment developed over the last year.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America ("GAAP" accounting) are the financial statements are presented in US dollars. The Company has adopted a December 31 fiscal year end.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of assets requires management to make estimates and assumptions that affect the reported amounts and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and the expenses during the reporting period. Actual results could differ from those estimates.

Financial Instruments

The carrying value of the Company's financial instruments approximates their fair value because of the short maturity of these instruments.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Use of net operating loss carry forwards for income tax purposes may be limited by Internal Revenue Code section 382 if a change of ownership occurs.

Basic Income (Loss) Per Share

Basic income (loss) per share is calculated by dividing the Company's net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company's net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of March 31, 2011

Dividends

The Company has not adopted any policy regarding payment of dividends. No dividends have been paid during any of the periods shown.

Impairment of Long-Lived Assets

The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered t

Impairment of Long-Lived Assets (Continued)

through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be

disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

Advertising Costs

The Company's policy regarding advertising is to expense advertising when incurred.

Revenue Recognition

The Company recognizes revenue when products are fully delivered or services have been provided and collection is reasonably assured.

Stock-Based Compensation

Stock-based compensation is accounted for at fair value in accordance with SFAS No. 123 and 123 (R) (ASC 718). To date, the Company has not adopted a stock option plan and has not granted any stock options.

New Authoritative Accounting Guidance

On July 1, 2009, the Accounting Standards Codification ("ASC") became the Financial Accounting Standards Board ("FASB") officially recognized source of authoritative U.S. generally accepted accounting principles applicable to all public and non-public non-governmental entities, superseding existing FASB, AICPA, EITF and related literature. Rules and interpretive releases of the SEC under the authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. All other accounting literature is considered nonauthoritative. The switch to the ASC affects the way companies refer to U.S. GAAP in financial statements and accounting policies. Citing particular content in the ASC involves specifying the unique numeric path to the content through the Topic, Subtopic, Section and Paragraph structure.

FASB ASC Topic 260, "Earnings Per Share." On January 1, 2009, the Company adopted new authoritative accounting guidance under FASB ASC Topic 260, "Earnings Per Share," which provides that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method.

FASB ASC Topic 820, "Fair Value Measurements and Disclosures." New authoritative accounting guidance under ASC Topic 820, "Fair Value Measurements and Disclosures," affirms that the objective of fair value when the market for an asset is not active is the price that would be received to sell the asset in an orderly transaction, and clarifies and includes additional factors for determining whether there has been a significant decrease in market activity for an asset when the market for that asset is not active. ASC Topic 820 requires an entity to base its conclusion about whether a transaction was not orderly on the weight of the evidence. The new accounting guidance amended prior guidance to expand certain disclosure requirements. The Company adopted the new authoritative accounting guidance under ASC Topic 820 during the first quarter of 2009. Adoption of the new guidance did not significantly impact the Company's consolidated financial statements.

Further new authoritative accounting guidance (Accounting Standards Update No. 2009-5) under ASC Topic 820 provides guidance for measuring the fair value of a liability in circumstances in which a quoted price in an active market for the identical liability is not available. In such instances, a reporting entity is required to measure fair value utilizing a valuation technique that uses (i) the quoted price of the identical liability when traded as an asset, (ii) quoted prices for similar liabilities or similar liabilities when traded as assets, or (iii) another valuation technique that is consistent with the existing principles of ASC Topic 820, such as an income approach or market approach. The new authoritative accounting guidance also clarifies that when estimating the fair value of a liability, a reporting entity is not required to include a separate input or adjustment to other inputs relating to the existence of a restriction that prevents the transfer of the liability. The forgoing new authoritative accounting guidance under ASC Topic 820 will be effective for the Company's consolidated financial statements beginning October 1, 2009 and is not expected to have a significant impact on the Company's consolidated financial statements.

FASB ASC Topic 825 "Financial Instruments." New authoritative accounting guidance under ASC Topic 825, "Financial Instruments," requires an entity to provide disclosures about the fair value of financial instruments in interim financial information and amends prior guidance to require those disclosures in summarized financial information at interim reporting periods.

New Authoritative Accounting Guidance (continued)

FASB ASC Topic 855, "Subsequent Events." New authoritative accounting guidance under ASC Topic 855, "Subsequent Events," establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or available to be issued. ASC Topic 855 defines (i) the period after the balance sheet date during which a reporting entity's management should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, (ii) the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements, and (iii) the disclosures an entity should make about events or transactions that occurred after the balance sheet date. The new authoritative accounting guidance under ASC Topic 855 became effective for the Company's financial statements for periods ending after June 15, 2009. Effective February 24, 2010, the FASB issued Accounting Standards Update ("ASU") No. 2010-09, "Subsequent Events (Topic 855): Amendments to Certain Recognition and Disclosure Requirements" which revised certain disclosure requirements. ASU No. 2010-09 did not have a significant impact on the Company's consolidated financial statements. The company evaluated subsequent events, which are events or transactions that occurred after March 31, 2011 through the issuance of the accompanying consolidated financial statements.

Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying consolidated financial statements

NOTE 4 - RELATED PARTY TRANSACTIONS

The Company received periodic advances from its principal stockholder based upon the Company's cash flow needs.

NOTE 5-COMMON STOCK

Articles of Incorporation Amendment and Stock Split - The Company's Certificate of Incorporation, as amended, authorizes the issuance of up to 50,000,000,000 shares of common stock at a par value of \$.000001 per share. Over the year ended September 30, 2010, the Company's Board of Directors ratified a two thousand to one reverse stock splits which became effective April 30, 2010. The Company's Board of Directors ratified a two thousand to one reverse stock split which became effective July 15, 2010. The Company's Board of Directors ratified a 3,000 for one reverse stock split which became effective June 4, 2011.

The share and per share data for all periods presented has been retroactively adjusted to reflect the stock splits

Debt Conversions - In November and December 2009, the Company entered into a Debt Conversion Agreement (the "Agreement") and issued 62.5 million shares of common stock at \$.032 per share to a debtor as full satisfaction for Note payables previously due. In February 2010 the company entered into a Debt Conversion Agreement (the "Agreements") and issued 100 million shares of common stock at \$.0005 as payment on Note payables previously due. In May 2010 the Company entered into a Debt Conversion Agreement (the "Agreement") and issued 500 million common stock at .0005 as partial settlement of the debt. In August 2010 the Company entered into a Debt Conversion Agreement (the "Agreement") and issued 12,000,200,000 shares as partial settlement of the debt. In December 2010 the Company entered into a Debt Conversion Agreement (the "Agreement") and issued 600 million common stock at an average of .0005 per share as partial settlement of debt. In March 2011 the Company entered into a Debt Conversion Agreement (the "Agreement") and issued 400 million common shares as a partial settlement of the debt. In March the Company received and canceled 12,000,000,000 shares and the debt conversion was canceled.

Restricted Share Issuances - In July and September 2009, 11.2 million shares were issued to a consultant for public market help for the company. In October 2009 980 million shares was issued for the acquisition of the Maden Acquisition Trust. On May 3, 2009 1.5 Billion shares were issued to management for service and raising additional funding for the company. In August 2010 29 Billion shares were issued to management for service and raising additional funding from the company.

Restricted Share Issuances (Continued)

Also in October 2009, the Company issued 250,000 shares of restricted Preferred B stock with a fair value of \$.001 per share or \$250 to the trustees of the Maden Trust. In 2009 and 2010 the Company issued 370,000 shares of preferred stock for services. In 2009 and 2010 the Company issued 107,057 shares of Preferred Stock for \$371,219 or an average price of \$3.47 per share. In July another \$143,337 was received for 83,662 shares of Preferred B-2 stock at \$1.71 per share.